NeuroPace (NPCE) Projected to Post Quarterly Earnings on Tuesday

Key Points

• NeuroPace will report Q1 2026 results after the market close on May 12, 2026 (earnings call 4:30 PM ET); analysts forecast ($0.19) EPS and $21.65M in revenue.
• In the prior quarter (reported March 3) NeuroPace beat estimates with EPS of ($0.08) versus a consensus of ($0.14) and revenue of $26.59M, but the company remains unprofitable with a negative net margin (~21.47%) and negative ROE (~105.67%), and analysts project ~($1) EPS for the current fiscal year.
• Market context: market cap ≈ $578.2M, 12‑month range $7.56–$18.98, high institutional ownership (78.83%), and a consensus rating of Moderate Buy with a consensus price target of $18.67.

NeuroPace (NASDAQ:NPCE - Get Free Report) is anticipated to announce its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $21.6480 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. The firm had revenue of $26.59 million for the quarter, compared to analysts' expectations of $24.79 million. NeuroPace had a negative net margin of 21.47% and a negative return on equity of 105.67%. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeuroPace Stock Performance

NPCE traded up $0.13 during midday trading on Tuesday, reaching $17.03. The company had a trading volume of 18,590 shares, compared to its average volume of 203,114. The company has a debt-to-equity ratio of 3.09, a quick ratio of 4.33 and a current ratio of 5.28. The stock has a market cap of $578.17 million, a PE ratio of -25.92 and a beta of 1.92. NeuroPace has a 12-month low of $7.56 and a 12-month high of $18.98. The business has a 50-day moving average price of $14.68 and a two-hundred day moving average price of $14.72.

Institutional Trading of NeuroPace

Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc lifted its stake in NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after purchasing an additional 1,239 shares in the last quarter. Quantbot Technologies LP purchased a new stake in NeuroPace in the 2nd quarter worth approximately $35,000. Quarry LP lifted its stake in NeuroPace by 94.9% in the 3rd quarter. Quarry LP now owns 3,845 shares of the company's stock worth $40,000 after purchasing an additional 1,872 shares in the last quarter. New York State Common Retirement Fund lifted its stake in NeuroPace by 755.6% in the 4th quarter. New York State Common Retirement Fund now owns 7,700 shares of the company's stock worth $119,000 after purchasing an additional 6,800 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in NeuroPace in the 4th quarter worth approximately $184,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on NPCE shares. Cantor Fitzgerald upgraded shares of NeuroPace to a "strong-buy" rating in a research note on Wednesday, March 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of NeuroPace in a research note on Friday, March 27th. UBS Group reiterated a "buy" rating on shares of NeuroPace in a research note on Wednesday, January 14th. Wall Street Zen cut shares of NeuroPace from a "buy" rating to a "hold" rating in a research note on Sunday, March 15th. Finally, Wells Fargo & Company upgraded shares of NeuroPace to a "strong-buy" rating in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NeuroPace currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.67.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company's mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company's flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.